Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: A randomised, double-blind, placebo-controlled, phase 3 study

The Lancet Diabetes and Endocrinology

Volumn 4, Issue 3, 2016, Pages 211-220

  Weber, Michael A ^a   Mansfield, Traci A ^b   Cain, Valerie A ^b   Iqbal, Nayyar ^b   Parikh, Shamik ^b   Ptaszynska, Agata ^c  

^a SUNY Downstate Medical Center   (United States)

^b ASTRAZENECA   (United Kingdom)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DAPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; PLACEBO; THIAZIDE DIURETIC AGENT; URIC ACID; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIHYPERTENSIVE AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; ARTICLE; BACTERIURIA; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SYSTOLIC BLOOD PRESSURE; TREATMENT WITHDRAWAL; URIC ACID BLOOD LEVEL; URINARY TRACT INFECTION; WEIGHT CHANGE; AGED; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECTS; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 84959460390     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(15)00417-9     Document Type: Article

References (27)

1. Standards of medical care in diabetes. Diabetes Care 2015, 38(suppl 1):S1-S94. American Diabetes Association.
2. Muskiet MH, Tonneijck L, Smits MM, Kramer MH, Lambers Heerspink HJ, van Raalte DH Pleiotropic effects of type 2 diabetes management strategies on renal risk factors. Lancet Diabetes Endocrinol 2015, 3:367-381.
3. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens 2014, 16:14-26.
4. Bailey CJ, Day C SGLT2 inhibitors: glucuretic treatment for type 2 diabetes. Br J Diabetes Vasc Dis 2010, 10:193-199.
5. Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008, 51:1145-1149.
6. Farxiga (dapagliflozin) tablets. Highlights of prescribing information 2014, FDA, US Food and Drug Administration, (accessed Oct 15, 2015). http://www1.astrazeneca-us.com/pi/pi_farxiga.pdf.
7. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 375:2223-2233.
8. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011, 13:928-938.
9. Wilding JP, Norwood P, T'Joen C, Bastien A, List JF, Fiedorek FT A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009, 32:1656-1662.
10. Woo V, Langkilde AM, Sugg J, Parikh S Blood pressure reduction with dapagliflozin in patients with type 2 diabetes and cardiovascular disease. Circulation 2013, 128(suppl 22):A10606.
11. Woo V, Langkilde AM, Parikh S Dapagliflozin, a novel antihyperglycemic agent that promotes urinary glucose excretion, reduces systolic blood pressure in patients with type 2 diabetes mellitus. Circulation 2011, 124(suppl 21):A9520. (abstr).
12. Basile J, Ptaszynska A, Ying L, Sugg J, Parikh S The effects of dapagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus. Circ Cardiovasc Qual Outcomes 2012, 5:A59.
13. Sjostrom CD, Johansson P, Ptaszynska A, List J, Johnsson E Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes. Diab Vasc Dis Res 2015, 12:352-358.
14. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 2013, 15:853-862.
15. Yavin Y, Mansfield TA, Ptaszynska A, et al. Hyperkalemia incidence with the SGLT2 inhibitor dapagliflozin. Diabetes 2014, 63(suppl 1):1086-P.
16. Standards of medical care in diabetes-2009. Diabetes Care 2009, 32(suppl 1):S13-S61.
17. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
18. Calhoun DA, Lacourciere Y, Chiang YT, Glazer RD Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension 2009, 54:32-39.
19. Pickering TG, Shimbo D, Haas D Ambulatory blood-pressure monitoring. N Engl J Med 2006, 354:2368-2374.
20. Kannel WB Elevated systolic blood pressure as a cardiovascular risk factor. Am J Cardiol 2000, 85:251-255.
21. The clinical management of primary hypertension in adults. Clinical Guideline 127 2011, NICE, UK National Institute for Clinical Excellence, (accessed Oct 15, 2015). https://www.nice.org.uk/guidance/cg127.
22. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2014, 8:262-275. e9.
23. Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 2015, 38:420-428.
24. Weber MA, Mansfield TA, Alessi F, Ptaszynska A Effects of dapagliflozin on blood pressure in diabetic patients with hypertension inadequately controlled by a renin-angiotensin system blocker. Circulation 2013, 128:A13144. (abstr).
25. Sica DA, Carter B, Cushman W, Hamm L Thiazide and loop diuretics. J Clin Hypertens 2011, 13:639-643.
26. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC Hypothesis: β-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 2001, 37:250-254.
27. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015, published online Sept 17. 10.1056/NEJMoa1504720.